Iterative Health
Sloane Allebes Phillips has a diverse work history. Sloane started their career in 2008 as a Monitoring Coordinator at Vivint, a smart home company. From 2012 to 2014, Sloane served as the Director of Development at Women's World Health Initiative, where they focused on improving healthcare access for women in developing countries. In 2014, Sloane joined the Peace Corps as a Health Extension Volunteer before transitioning to Planned Parenthood League of Massachusetts in 2014. At Planned Parenthood, they held two roles - Annual Giving Coordinator and Manager, Office of the President. Currently, Sloane is working at Iterative Health as the VP of Data Operations, where they are involved in developing scalable technology to reduce healthcare disparities.
Sloane Allebes Phillips completed their Master of Business Administration (MBA) degree from the MIT Sloan School of Management in 2019. Prior to that, they earned a Bachelor of Science (B.S.) in Public Health from Brigham Young University in 2012. It is not specified when they attended Brigham Young University–Hawaii or if they obtained any degree from there. Additionally, Sloane has obtained a certification as a Certified Nonprofit Professional (CNP) from the Nonprofit Leadership Alliance, although the specific month and year of obtaining this certification are not mentioned.
This person is not in any teams
This person is not in any offices
Iterative Health
1 followers
Iterative Health is pioneering the use of artificial intelligence-based precision medicine in gastroenterology (GI), with the aim of helping to optimize clinical trials investigating treatment of inflammatory bowel disease (IBD). We use advanced machine learning and computer vision to interpret endoscopic images along with other types of data, helping clinicians to better assess patients with potential GI problems. This gives practitioners enhanced capabilities in the detection, annotation, disease scoring and treatment of GI related diseases. Iterative Health is initially applying these advances towards standardizing disease severity characterization for inflammatory bowel disease. Ultimately, the company aims to establish more meaningful endpoints to serve as better predictors of both therapeutic response and disease outcomes. The company is headquartered in Cambridge, Massachusetts.
Employees
51-200